For example, treatment of mutant KRAS-driven PDAC tumours with the combination of gemcitabine and SLC-0111 results in acidosis and cell death, and prolongs survival by tumour-bearing mice (McDonald et al., 2019). The gene discussed is KRAS; the disease is neoplasm.